In Harris, Biden picks a running mate with ‘Big Pharma’ in her sights
Joe Biden, the Democratic nominee for president, announced Sen. Kamala Harris of California as his vice presidential pick yesterday, potentially elevating a vocal pharmaceutical industry critic into the No. 2 role in government.
Harris, who sought the 2020 nomination herself, launched her presidential campaign with an aggressive proclamation about the drug industry: “Big pharmaceutical companies,” she said during her kickoff speech, “have unleashed an opioid crisis from the California coast to the mountains of West Virginia.”
As senator and, previously, as California’s attorney general, Harris made the opioid crisis a bread-and-butter issue, joining a 2016 lawsuit against Indivior for misleading marketing. After joining the 2020 race, she followed up with an aggressive platform on drug prices: an international price index, threats to use “march-in” rights on drug industry intellectual property, and preventing drug companies from using advertising expenses as tax write-offs.
Harris, who sought the 2020 nomination herself, launched her presidential campaign with an aggressive proclamation about the drug industry: “Big pharmaceutical companies,” she said during her kickoff speech, “have unleashed an opioid crisis from the California coast to the mountains of West Virginia.”
As senator and, previously, as California’s attorney general, Harris made the opioid crisis a bread-and-butter issue, joining a 2016 lawsuit against Indivior for misleading marketing. After joining the 2020 race, she followed up with an aggressive platform on drug prices: an international price index, threats to use “march-in” rights on drug industry intellectual property, and preventing drug companies from using advertising expenses as tax write-offs.
.png)
No hay comentarios:
Publicar un comentario